Asha Neuromodulation Clinics and NeuraLight Partner to Advance Precision Mental Health
Partnership brings brain-function measurement into India’s leading neuromodulation clinical networks
TEL AVIV, Israel & HYDERABAD, India, [DATE], 2026: NeuraLight and Asha Neuromodulation Clinics (ANC) today announced a strategic partnership to bring a new level of precision to interventional psychiatry. By integrating NeuraLight’s quantitative brain function biomarkers with Deep Transcranial Magnetic Stimulation (Deep TMS), the collaboration aims to advance more sensitive, objective assessment of treatment response, laying the foundation for more personalized approaches to psychiatric treatment.
Asha Neuromodulation Clinics (ANC) is a pioneer in advanced psychiatric care and India’s first multi-center Deep TMS network. With a growing network of specialized clinics across multiple cities and thousands of patients treated, ANC is advancing care for major depression, OCD, and other psychiatric conditions across India. The partnership combines ANC’s neuromodulation expertise with NeuraLight’s AI-powered brain function biomarkers, aiming to transform psychiatric treatment from subjective assessment to precise, objective measurement, enabling clinicians to better personalize and optimize treatments to improve patient outcomes.
“We want ANC to be a place where the future of Interventional Psychiatry is not only delivered, but developed,” said Dr. M S Reddy, leading psychiatrist and Director of ANC. “Combining our clinicians’ deep expertise in advanced neuromodulation with NeuraLight’s precision biomarkers will enable us to better understand how patients respond to treatment, refine our clinical approaches, and push the boundaries of personalized psychiatric care.
The partnership marks NeuraLight’s expansion into mental health, starting with major depression and OCD, bringing its AI-powered brain biomarkers into clinical treatment in one of the world’s largest healthcare markets.
“Mental health is one of the largest and fastest-growing areas of healthcare, yet the effects of treatments remain remarkably difficult to measure and optimize,” said Edmund Ben-Ami, CEO and Co-Founder of NeuraLight. “We’re bringing our proven precision in measuring treatment effects in drug trials into patient care, helping clinicians optimize treatments and improve outcomes.”